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| INTRODUCTION
Natural naphthoquinone derivatives have been widely identified as functional metabolites from various plants, microbes, marine organisms, etc. [1] Important cellular biological and pharmacological properties of natural naphthoquinones are recognized by numerous studies; for instance, the plant and intestinal bacteria sourced vitamin K 1 and K 2 are the vital factors in the blood-clotting response, lack of which dramatically increases the risk of coagulopathy. [2] Especially in some generally used medicinal herbals, naphthoquinones such as shikonin and plumbagin are validated as the major efficacy components exerting antimicrobial, insecticidal, antiphlogistic, wound healing, and other effects. [3, 4] Beyond the traditional medicinal applications is the awareness of naphthoquinones' antitumor potential. [5] A number of naphthoquinone analogs have been designed and evaluated for their pharmacological profile, along with those natural naphthoquinones. On this basis, mechanism research has been conducted to reveal the molecular biological roles of both naturally occurring and synthetic naphthoquinones in exposed cells. In structure, naphthoquinones are naphthalene derivatives bearing two carbonyl oxygen atoms. Even though there are several isoforms of naphthoquinones in theory, the most stable and widely reported one is 1,4-naphthoquinone. Based on this scaffold, a big class of efficacious analogs *These two authors contributed equally to this paper.
has been discovered including simple modified naphthoquinones, for example, Lawsone, shikonin, Juglone, plumbagin, menadione (also known as synthetic vitamin K 3 ), Methoxynaphthoquinone, and more complicated derivatives such as anthraquinone Doxorubicin and naphthoquinone epoxide Napabucasin. [6] [7] [8] [9] By contrast, less bioactive cases have been reported for 1,2-naphthoquinones and even less for the rare occurrence 2,6-naphthoquinones ( Figure 1) . Notable is the structural feature endows naphthoquinones with chemically active property. They may be reduced by different enzymes into semiquinones or hydroxynaphthalenes in cells. [10, 11] The chemical space also makes naphthoquinones stable ligands for several pathologic targets, and in some cases, naphthoquinones may be the chemotype preference for developing new inhibitors. [12] It is on this knowledge that we conclude the bioactive mechanisms of naphthoquinones into oxidant and non-oxidant mechanisms and introduce representative naphthoquinones mainly exerting anticancer efficiency in each manner.
| IN AN OXIDANT-DEPENDENT MANNER
Many naturally occurring and synthetic naphthoquinones, typically Juglone, plumbagin, 1,4-naphthoquinone, and menadione, have long been elucidated to possess impressive pharmacological activities. While these naphthoquinones may be able to interact with traditionally validated therapeutic targets, such as alter kinase activity and activate/inactivate signaling pathway, on the other side, they are well characterized as redox to induce the ascending level of oxidant stress in exposed cells, which is ascribed to be a vital mechanism for their cytotoxicity (Figure 2 ). [13] The redox role of assimilated naphthoquinones in exposed cells is nothing unexpected, for their being in the source organisms in most cases is to participate in the electron transferring and biological oxidative processes. [14] 3 | VIA OXIDANT STRESS and stepwise hydroquinone, NADPH quinone reductase directly carries out the transformation from naphthoquinone to hydroquinone. The oxidation of semiquinone into quinone consumes oxygen and yields ROS which will be handled by antioxidases and dismutases. [16, 17] In untreated cells, the conversion between quinone, semiquinone, and hydroquinone is in a delicate equilibrium state and performs certain biological functions. However, when cells are exposed to naphthoquinones, the level of semiquinone and hydroquinone increases and hence produces additional ROS. While the additional ROS may bring damage to various biomolecules, excessive semiquinone may also covalently bind to membrane, nucleic acids, and proteins. As a consequence, when the cellular oxidant stress overwhelms the capacity of treated cells, cellular molecules including proteins, lipids, DNA, and RNA are irreversibly damaged and therefore cause cell death. [18] Carcinoma cells suffer from a highly oxidant condition, for the rapid proliferation leads to the colonizing areas aloof from blood vessels and therefore hypoxia. During the pathological propagation period, tumor cells usually accumulate a higher ROS level than normal cells. In addition, a loss of reducing activity in tumor cells with a relatively low level of reductive biomolecules (GSH, for instance) or antioxidases/ dismutases also contributes to the inability of eliminating oxidant stress. [19] Normal tissues, on the contrary, are better tolerated to the uptake of ROS-inducing agents. Hence, the tumorous feature of sensitive to oxidant stress provides an appealing strategy in cancer treatment: In a sublethal dose usage for normal cells, naphthoquinones exhibit an obvious selectivity toward cancer cells and are often tested as enhancers in radiotherapies.
AND ALKYLATION
The ROS-induction effect of naphthoquinones is related to the structural modification on the scaffold, which also contributes to the alkylation tendency of naphthoquinones. Entities with electrophilic and accessible C3 position are apt to alkylate on nucleophile molecules, such as thiols and amines, to form adducts and consume reducing substance pools. [20] Taken as an example, menadione is observed to take part in the redox cycling with a higher rate, compared to the other two vitamin K forms, viz. K 1 and K 2 . More proportion of one-electron reduction is engaged in the K 3 cycling and results in a higher output of ROS; also, vitamin K 3 is apt to alkylate on GSH and other sulphydrylcontaining proteins via a Michael addition reaction. On the contrary, Lawsone with a hydroxyl on C2 position is a weak alkylating agent, and its ROS-inducing capability is much lower than those of 1,4-naphthoquinone, menadione, Juglone, or plumbagin.
[11]
| VIA ROS-RELATED PATHWAYS
As the oxidation and alkylation progress, the intricate signaling network can be triggered by the oxidant stress. The oxidant stress has been validated as the stimulating factor for several pathways including nuclear factor κB (NF-κB), epidermal growth factor receptor (EGFR), PI3K-mTOR, receptor tyrosine kinase (RTK), and mitogenactivated protein kinases (MAPK) signaling pathways. [21] The activation of EGFR and ErbB2 signaling pathways, for example, has been detected to be involved in the formation of ROS induced by alkylating naphthoquinones of 1,4-naphthoquinone, menadione, Juglone, and plumbagin; interestingly, the same stimulation on these pathways has not been observed in cellular assays when treated with Lawsone and Lapachol, whose oxidant activity and cytotoxicity are much lower. [22] It is not certain yet to which degree the oxidant stress-triggered pathways contribute to the biological functions of naphthoquinones; however, it reveals that the modification on the scaffold of naphthoquinone could dramatically impact the oxidizing efficacy and hence relating bioactivity. So far, it is well established many naphthoquinones, especially simple modified naturally occurring whose C3 position is accessible and apt for alkylation, primarily exert anticancer activity in an oxidant-dependent manner.
| IN NON-OXIDANT MANNERS
Even though most naphthoquinone derivatives exhibited ROS-inducing property in a varying extent, some are also validated to implement bioactive functions via a more traditional way of binding with certain targets independent of oxidant stress, especially for the entities with mild oxidizability. The most elucidated mechanisms include targeting STAT3 and DNA topoisomerase, both with approved drugs entered the pharmaceutical market.
| VIA STAT3 INHIBITION
Of interest is the performance of naphthoquinone scaffold in the development of selective STAT3 (signal transducer and activator of transcription 3) inhibitors. STAT3 is a key mediator transferring extracellular signals into cell nucleus to regulate various cellular processes including proliferation, apoptosis, angiogenesis, and other biological activities. [23] [24] [25] [26] The activation of STAT3 is through the phosphorylation of the Tyr705 residue in SH2 domain and contributes to carcinogenesis and tumor progression when the activation is aberrantly up-regulated. [27, 28] Great efforts have been devoted to identify potent inhibitors that hold promise for suppressing STAT3 activation, of which a considerable proportion is comprised by various naphthoquinones. [29] Recent studies showed that plumbagin and shikonin possess the potential of inhibiting STAT3 activity, [30] [31] [32] while previous research has already identified several agents in naphthoquinone scaffold by detailed surveys. Supporting cases contain the synthetics including LLL-3, LLL-12, and LY-5, [33, 34] along with naturally occurring naphthoquinones including STA-21, Cryptotanshinone (CPT), and Napabucasin [35] [36] [37] ( Figure 3 ). From this point of view, a chemical preference for naphthoquinones might be hinted in the STAT3 inhibitor development.
In a serial of rational design processes, Lin et al. have reported the discovery and optimization for potent STAT3 inhibitors LLL-3, LLL-12, and LY-5. By the virtual simulation work, the 1,4-naphthoquinone scaffold showed a crucial role in binding with SH2 domain of STAT3. Based on the analysis of interaction mode between hit compounds and protein STAT3, the starting compounds were gradually optimized to afford the final agents. Dramatic decrease in STAT3 activation was observed when exerting the reported compounds in vitro, and the following pathway was also blocked efficiently. [33, 38] The naturally occurring extracts, especially from the traditional Chinese herbals, attract much attention in the STAT3 inhibitor study. CPT, a 1,2-naphthoquinone epoxide isolated from the root of the Chinese herbal medicine Salvia miltiorrhiza Bunge, proves to exert potential anticancer activity through targeting STAT3. [39, 40] It binds to the SH2 domain of STAT3 and specifically blocks the phosphorylation of residue Tyr705 and hence the dimerization of STAT3. [37] The anticancer effect of CPT is involved with inducing apoptosis and cell cycle arrest via the inhibition of the STAT3 signaling pathway. Also, it is suggested the inhibition of STAT3 activity by CPT is direct and independent of the upstream regulators in human prostatic cancer. STA-21, a natural product containing 1,4-naphthoquinone backbone, was first identified as an angucycline antibiotic and has entered the Phase I/II clinical trials for psoriasis. [41] However, in a structure-based virtual database screening, STA-21 was validated as a [42] The remarkable milestone in exploiting STAT3 inhibitor is the approval of Napabucasin by FDA in late 2016 as an orphan drug in the treatment of gastric/gastroesophageal junction (GEJ) or pancreatic cancer. Napabucasin is a 1,4-naphthoquinone epoxide originally extracted from Bignoniaceae tabebuia which shows direct STAT3 inhibitory activity and beyond that is a first-in-class cancer stemness inhibitor. [43] Cancer stem cells (CSCs) are subpopulations of cancer cells with extremely high tumorigenic potential, responsible for cancer formation and maintenance, and contribute to the resistance against conventional chemotherapy, radiotherapy, and targeted agents. STAT3 is suggested to be the vital factor for maintaining cancer stemness and constitutively active in CSCs. Assays on Napabucasin in xenograft tumor models illustrated that it down-regulated gene transcription driven by STAT3 and inhibited the expressions of CSC markers, along with blocking spherogenesis and causing cell death of CSCs in several cancers. [44] What is more, it prevented pancreatic cancer relapse and metastasis, but did not affect hematopoietic stem cells. Trials of Napabucasin in combination with other anticancer agents demonstrated even elevated efficacies. [45, 46] 7 | DNA TOPOISOMERASE DNA topoisomerase is another appealing target in the application of naphthoquinone-based agents as antineoplastic drugs, with several inhibitory entities approved in clinical treatment. This enzyme is highly conserved and capable of altering DNA topography to relieve torsional strain during processes like DNA replication, transcription, repair, and other nuclear processes. [47, 48] In mammalian cells, two distinct types of DNA topoisomerase are reported, performing functions by introducing transient protein-DNA breaks on either one (Top I) or both DNA strands (Top II). Both topoisomerases are overexpressed in tumor cells, which is in accordance with the pathologically rapid proliferation. β-Lapachone is a naturally occurring 1,2-naphthoquinone epoxide isolated from Tabebuia avellanedae, whose antitumor effects have been extensively studied for a long period. Research shows that the antitumor activity of β-Lapachone is correlated with the inhibition of DNA topoisomerase activities, and current opinions mainly agree that β-Lapachone serves as an inhibitor for both Top I and Top II. [51, 52] According to the TrialClinicals (http://www.clinicaltrials. gov), β-Lapachone has already completed Phase II trials for the treatment of pancreatic cancer and squamous cell carcinoma of the head and neck. A Phase II trial on safety and efficacy of β-Lapachone in patients with leiomyosarcoma has also been conducted. In addition, analog ARQ 761, a prodrug of β-Lapachone with a better soluble profile, has aroused much attention and entered Phase I trials.
In more depth is the research on a serial of 1,4-naphthoquinone-based anthracycline derivatives as antineoplastic agents, viz. Aclarubicin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Pirarubicin, Pixantrone, Sabarubicin, and Valrubicin ( Figure 4 ). In fact, the anthracyclines provide effective solutions to a broader spectrum of tumors than any other types of chemotherapy agents, including leukemia, lymphoma, metrocarcinoma, ovarian cancer, breast cancer, bladder cancer, and lung cancer. [53] Originally, Aclarubicin, Daunorubicin, and Doxorubicin were extracted from the bacteria Streptomyces, and the other agents were their synthesis or semisynthesis analogs, to optimize biochemical properties and improve therapeutic efficacy. The typical molecular mechanisms of these anthraquinones are performed mainly through inhibiting Top II activity, along with intercalating into DNA strains and inducing ROS generation. [54] While the combination of these bioactivities contributes to the impressive antitumor effect, it is also the main cause of anthraquinones' irreversible cardiotoxicity, as cardiac tissues contain high level of Top IIβ and lack ROS relieving substances. [55] Multiple strategies have been applied to attenuate their detrimental effects: The rational design endows the synthetic fewer side effects compared to the naturally occurring, for example, Epirubicin has a faster elimination and reduced toxicity over its isomer Doxorubicin, and Pixantrone is selective for Top IIα whose expression is dramatically elevated in cancer cells, rather than inhibitory to both Top IIα and Top IIβ indiscriminately [56] ; administration of antidote with the anthraquinone agents may also help to relieve the detrimental effects, for instance, co-administration of Dexrazoxane obviously attenuates Doxorubicin-induced cardiotoxicity [57] ; another successful strategy to increase therapeutic index and spectrum of activity in clinical settings is to alter the dosage form, for example, the liposomal Doxorubicin has a more favorable pharmacokinetics for its releasing from the liposomes is only at the tumorous interstitial fluid due to the relatively high local concentration of ammonia, continuously produced there as a result of glutaminolysis. [58] So far, the exploration of the mentioned anthraquinones has achieved significant results, with most of them are approved and the rest under clinical testing for the treatment of a variety of tumors (Table 1) . Still, other endeavors have been directed at the development of novel analogs with better characteristics or the trials in combination with other chemotherapy drugs: Pirarubicin, an analog of Doxorubicin which is in Phase II trial, has less cardiotoxicity than Doxorubicin and exhibits activity against some Doxorubicin-resistant cell lines [59] ; another recent case occurred in late 2016, when the combination of Lartruvo and Doxorubicin was approved for the treatment of STS (soft tissue sarcoma) which cannot be cured by radiation or surgery and for which an anthracycline (chemotherapy) is an appropriate treatment.
| MISCELLANEOUS
While some naphthoquinones could potently alter the activity of a certain target, actually most of the naphthoquinones are usually found to be involved in a multifunctional mechanism of actions and hence may be exploited as multitarget drugs (MTDs). [60] Streptonigrin (STN), a naturally occurring 1,4-naphthoquinone analog, has demonstrated inhibitory potency toward a broad spectrum of cancers including melanoma, breast, lung, lymphoma, as well as head and neck cancer. Diverse functional mechanisms contribute to the bioactivity of STN, comprised of block of DNA synthesis and impairment to DNA strains, along with the interference to electron transference of the respiratory chain. [61] Likewise, many other naphthoquinone derivatives, especially the naturally occurring which are generally used as modification starting points, exert their molecular functions in a promiscuous way. Currently, the most extensively studied natural naphthoquinones, such as plumbagin and shikonin, have aroused much attention in the drug development field. Plumbagin, an analog of vitamin K3, is found in the root of Plumbaginaceae plants and possesses diverse pharmacological properties. [62, 63] Studies have reported that plumbagin exerts anticancer effects via multiple signaling pathways, including AMP-activated protein kinase (AMPK) signaling pathway, [64] mitogen-activated protein kinases (MAPK) signaling pathway, [65] Wnt signaling pathway, [66] and STAT3 signaling pathway, [30] other than the ROS-inducing effect and oxidant stress-related pathways. Besides, the activity of plumbagin's inhibiting cell proliferation and inducing cell apoptosis is also correlated with the disruption of microtubules dynamics through tubulin binding. Irreversibly, plumbagin binds to tubulin at the colchicine binding site and inhibit both the rate and the extent of tubulin polymerization. [67] The application of plumbagin in cancer therapy has been limited due to its low aqueous solubility and the side-effects. Nano-drug delivery systems and other pharmaceutic strategies may encapsulate plumbagin effectively to overcome poor water solubility, prolong circulation half-life time, reduce the side-effects, and ameliorate the anticancer efficacy. [68] [69] [70] Also, a great amount of efforts have been dedicated to the development of plumbagin derivatives for the purpose of improving molecular properties and pharmacological profile. [71] Shikonin is another plant-based secondary metabolite belonging to 1,4-naphthoquinone and is extracted from the root of Lithospermum erythrorhizon. Although a wide spectrum of biological activities has been reported, shikonin and its derivatives have attracted most attention due to their striking anticancer activities. [72] [73] [74] However, its exact mechanisms underlying the anticancer activities remain obscure, including cell apoptosis, cell necrosis, inhibition of DNA Top II activity, and regulation of a diverse range of tumor cell signaling pathways. [75] [76] [77] [78] Increasing studies also indicated that shikonin and its derivatives disrupt microtubules dynamics and disorganize spindle microtubules. [79] While shikonin and its analogs were initially identified as microtubule-destabilizing agents inducing microtubule depolymerization, [80, 81] interestingly, Lin et al. [82] have reported novel shikonin derivatives containing heterocycle bound well to the tubulin at paclitaxel binding site, leading to the enhancement of tubulin polymerization and mitotic disruption. Several reports indicated that shikonin and its analogs could circumvent cancer drug resistance and may be potential candidates for cancer therapy avoiding induction of drug resistance. [83] Promise thus be hinted in the future research of developing shikonin derivatives into long-term used antineoplastic agents.
| CONCLUSION
It has been a controversial topic for long to employ the naphthoquinones or more radically, quinones, as candidates in the drug design process. Pains have been experienced repeatedly in the ambitious HTS (high-throughput screening) campaigns for a large proportion of "hits" were finally confirmed as PAINS (pan assay interference compounds), with quinone being one of the representative chemical scaffolds. Since then, many medicinal chemists have ranked quinones as notorious troublemakers. [84] However, this claim partially conflicts with the long application history of natural naphthoquinones in the medicinal use. And if naphthoquinones were rigorously swept aside in the drug developing process, a number of approved or in preclinical/ clinical testing naphthoquinone agents (in cancer therapy or other aspects) shall never be discovered. It is no wonder for the pharmaceutical industry takes an ambivalent attitude toward naphthoquinone derivatives. They are usually endowed with potential to exert pleiotropic effects in cells, which brings opportunities but simultaneously also risks. [85] And indeed, to a large extent, the redox cycling and ROS-inducing effect of naphthoquinones reinforce their interaction complexity with biological systems. From a conventional viewpoint, the versatile functional mechanisms are hard to be thoroughly explained and hence undoubtedly undesirable; however, from a more evolving standpoint, multitargeting property might be employed as synergic polypharmacology in the chemotherapies. The combination of pharmacological activities may also put forward an efficient resolution to the resistant cells, as cases are reported frequently that many naphthoquinone derivatives performed well in repressing the resistant tumors. Besides, the adverse effects of naphthoquinones may be lowered by structural modification, co-administration of attenuated medicine, or suitable delivery system, as mentioned above. After all, it is a more important characteristic rendering active drugs minor side-effects than identifying their molecular targets to reach the pharmaceutical market. [86] So far, a number of naphthoquinone-based agents have been employed for cancer therapies, and most of them are anthraquinones rather than simple naphthoquinones, whose antitumor efficacy for now remains "potential." Yet, this potential is more and more likely to be realized by rational modification to employ the simple naphthoquinones as modification starting point, rather than utilize them in their original form. Besides, the simple naphthoquinones are easy to be modified and optimized, compared to the complicated ones. The design of naphthoquinone-based derivatives as anticancer agents has already been proven effective in clinical treatment, and the continuous digging of potential naphthoquinones as privileged structures shall keep on providing a range of effective strategies for cancer therapies.
